Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Development > SPI-1620

SPI-1620Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

An endothelin B receptor agonist

Target Indications

  • Adjunct therapy in solid tumors

Route of Administration

  • Intravenous

Mode of Action

  • A highly selective endothelin B receptor agonist.
  • In animal models SPI-1620 increased delivery of anticancer agents to the tumor

SPI-1620

Figure 1. Schematic diagram showing mechanism of selective and transient increase in blood flow to tumors following treatment with SPI-16201,2

SPI-1620 is a highly selective peptide agonist of endothelin-B receptors expressed on endothelial cells lining the interior surface of blood vessels. By stimulating the endothelin-B receptors on tumor vasculature, SPI-1620 should transiently modify blood flow, and increase delivery of anticancer agents to the tumor.

Status

References:
1. Rajeshkumar N, Rai A, Gulati A. Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Research and Treatment. 2005. 94:237-47.

2. Anil Gulati and Kartike Gulati. Use of endothelin etb receptor agonists and eta receptor antagonists in tumor imaging. Patent application # EP20050824775.

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Market Opportunities

SPI-1620

Status

The current study is a Phase 1, open label, ascending dose study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of the endothelin B receptor agonist, SPI-1620, in patients with recurrent progressive carcinoma.

Market

Chemotherapy is one of the mainstays of therapy for solid carcinomas, including breast, lung, and prostate. Chemotherapy uses drugs called cytotoxic agents that are poisonous to cells and kill cancer cells, as well as rapidly dividing normal cells. Chemotherapy often fails because adequate and uniform distribution of the cytotoxic agents is not achieved in the tumor, and serious side effects can result from toxicity to normal cells. Consequently, any means to increase the delivery of a cytotoxic agent selectively to tumors, while minimizing its concentration in normal tissues may be very beneficial.

SPI-1620 is being developed as an adjunct to chemotherapy. In pre-clinical studies, when anti-cancer drugs, such as paclitaxel injection, are administered shortly after SPI-1620, the anti-cancer drug concentration in the tumor is increased several fold.

This results in increased antitumor efficacy at a given dose of a cytotoxic agent, and might allow physicians to maximize efficacy with reduced cytotoxic agent doses with resultant decreased toxicity to the normal organs.